OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share

OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced

OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 Shares

OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced